148 related articles for article (PubMed ID: 34003526)
41. The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms.
Ramalho LN; Ribeiro-Silva A; Cassali GD; Zucoloto S
Vet Pathol; 2006 Jul; 43(4):424-9. PubMed ID: 16846983
[TBL] [Abstract][Full Text] [Related]
42. Alteration of somatostatin receptor 2 expression in canine mammary gland tumor.
Sakai K; Yonezawa T; Yamawaki H; Oyamada T
J Vet Med Sci; 2015 Oct; 77(10):1319-22. PubMed ID: 25985817
[TBL] [Abstract][Full Text] [Related]
43. Expression of glutathione, glutathione peroxidase and glutathione S-transferase pi in canine mammary tumors.
Leonel C; Gelaleti GB; Jardim BV; Moschetta MG; Regiani VR; Oliveira JG; Zuccari DA
BMC Vet Res; 2014 Feb; 10():49. PubMed ID: 24565113
[TBL] [Abstract][Full Text] [Related]
44. Hormone Receptor Expression Analyses in Neoplastic and Non-Neoplastic Canine Mammary Tissue by a Bead Based Multiplex Branched DNA Assay: A Gene Expression Study in Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Samples.
Mohr A; Lüder Ripoli F; Hammer SC; Willenbrock S; Hewicker-Trautwein M; Kiełbowicz Z; Murua Escobar H; Nolte I
PLoS One; 2016; 11(9):e0163311. PubMed ID: 27649560
[TBL] [Abstract][Full Text] [Related]
45. Expression of Arginine Vasopressin Type 2 Receptor in Canine Mammary Tumours: Preliminary Results.
Benavente MA; Bianchi CP; Aba MA
J Comp Pathol; 2020 Aug; 179():36-40. PubMed ID: 32958145
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours.
Fuhrer D; Eszlinger M; Karger S; Krause K; Engelhardt C; Hasenclever D; Dralle H; Paschke R
Eur J Endocrinol; 2005 May; 152(5):785-90. PubMed ID: 15879365
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic efficacy of smear cytology and Robinson's cytological grading of canine mammary tumors with respect to histopathology, cytomorphometry, metastases and overall survival.
Dolka I; Czopowicz M; Gruk-Jurka A; Wojtkowska A; Sapierzyński R; Jurka P
PLoS One; 2018; 13(1):e0191595. PubMed ID: 29360854
[TBL] [Abstract][Full Text] [Related]
48. Reduced canine BRCA2 expression levels in mammary gland tumors.
Yoshikawa Y; Morimatsu M; Ochiai K; Ishiguro-Oonuma T; Wada S; Orino K; Watanabe K
BMC Vet Res; 2015 Jul; 11():159. PubMed ID: 26202431
[TBL] [Abstract][Full Text] [Related]
49. Canine Mixed Mammary Tumour as a Model for Human Breast Cancer with Osseous Metaplasia.
Saad ES; Milley KM; Al-Khan AA; Nimmo JS; Bacci B; Tayebi M; Day MJ; Richardson SJ; Danks JA
J Comp Pathol; 2017 May; 156(4):352-365. PubMed ID: 28449818
[TBL] [Abstract][Full Text] [Related]
50. Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer.
Antuofermo E; Miller MA; Pirino S; Xie J; Badve S; Mohammed SI
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2247-56. PubMed ID: 17982119
[TBL] [Abstract][Full Text] [Related]
51. Concurrent expression of cyclo-oxygenase-2 and epidermal growth factor receptor in canine malignant mammary tumours.
Guimarães MJ; Carvalho MI; Pires I; Prada J; Gil AG; Lopes C; Queiroga FL
J Comp Pathol; 2014 Jan; 150(1):27-34. PubMed ID: 24060154
[TBL] [Abstract][Full Text] [Related]
52. Downregulation of transforming growth factor β (TGFβ) and latent TGFβ binding protein (LTBP)-4 expression in late stage canine mammary tumours.
Klopfleisch R; Schütze M; Gruber AD
Vet J; 2010 Dec; 186(3):379-84. PubMed ID: 19836277
[TBL] [Abstract][Full Text] [Related]
53. Immunohistochemical study of IGF-I and IGF-II expression in canine mammary tumours: Prognostic and diagnostic role.
Ozmen O
Acta Vet Hung; 2020 Sep; 68(3):269-274. PubMed ID: 33221734
[TBL] [Abstract][Full Text] [Related]
54. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.
Bakirel T; Alkan FÜ; Üstüner O; Çinar S; Yildirim F; Erten G; Bakirel U
J Vet Med Sci; 2016 May; 78(4):657-68. PubMed ID: 26822118
[TBL] [Abstract][Full Text] [Related]
55. Vitamin D receptor expression in canine mammary gland and relationship with clinicopathological parameters and progesterone/oestrogen receptors.
Sánchez-Céspedes R; Fernández-Martínez MD; Raya A; Pineda C; López I; Millán Y
Vet Comp Oncol; 2018 Mar; 16(1):E185-E193. PubMed ID: 29178579
[TBL] [Abstract][Full Text] [Related]
56. Expression of Ccdc85C, a causative protein for murine hydrocephalus, in the mammary gland tumors of dogs.
Tanaka N; Izawa T; Takenaka S; Akiyoshi H; Yamate J; Kuwamura M
Histol Histopathol; 2017 Apr; 32(4):397-403. PubMed ID: 27457231
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical study of the expression of E-cadherin in canine mammary tumours.
Reis AL; Carvalheira J; Schmitt FC; Gärtner F
Vet Rec; 2003 May; 152(20):621-4. PubMed ID: 12790166
[TBL] [Abstract][Full Text] [Related]
58. Tumour-associated macrophages are associated with vascular endothelial growth factor expression in canine mammary tumours.
Raposo TP; Pires I; Carvalho MI; Prada J; Argyle DJ; Queiroga FL
Vet Comp Oncol; 2015 Dec; 13(4):464-74. PubMed ID: 24119241
[TBL] [Abstract][Full Text] [Related]
59. Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks.
Fish EJ; Irizarry KJ; DeInnocentes P; Ellis CJ; Prasad N; Moss AG; Curt Bird R
BMC Cancer; 2018 Aug; 18(1):832. PubMed ID: 30126376
[TBL] [Abstract][Full Text] [Related]
60. Analysis of Hypoxia-Inducible Factor-1α Expression Relative to Other Key Factors in Malignant Canine Mammary Tumours.
Shin JI; Lim HY; Kim HW; Seung BJ; Sur JH
J Comp Pathol; 2015; 153(2-3):101-10. PubMed ID: 26145724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
